Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Ablação Endovascular do Nervo Esplâncnico Maior Direito em Indivíduos com ICFEP (Rebalance-HF)

16 de setembro de 2026 atualizado por: Axon Therapies, Inc.

ABLAÇÃO ENDOVASCULAR DO NERVO ESPLÂNCNICO MAIOR DIREITO NA Ablação Endovascular do Nervo Esplâncnico Maior Direito em Indivíduos com ICFEP: Estudo de Viabilidade: Estudo de Viabilidade Controlado Randomizado - Estudo de Reequilíbrio HF

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

Visão geral do estudo

Descrição detalhada

Up to 150 people will take part in this clinical study.

Phase I of the REBALANCE-HF Study

The first part of the study took place between January 2021 and March 2023. During this phase, 116 patients participated. Researchers reviewed the results to learn whether the procedure appeared safe and whether it might help improve symptoms in people with heart failure with preserved ejection fraction (HFpEF).

This early review showed encouraging results in some patients. It also helped researchers identify a group of patients who seemed more likely to benefit from the procedure.

Phase II of the REBALANCE-HF Study:

The current phase of the study focuses on patients who have similar characteristics to those who responded well in Phase I. The goal is to confirm whether this group of patients may benefit most from the treatment and whether the procedure should be studied further in a larger future trial.

This study will take place at multiple hospitals and research centers.

Participants who qualify for the study will be randomly assigned to one of two groups:

  • Treatment group: The procedure is performed using the Satera Ablation System to treat a nerve called the greater splanchnic nerve.
  • Control (sham) group: A simulated procedure is performed, but the treatment itself is not delivered.

Participants will be assigned to a group by chance, similar to flipping a coin, although twice as many patients will receive the treatment as the sham procedure (2:1 ratio).

The group assignment will happen during the procedure after anesthesia is given, and only after the doctor confirms that the patient's anatomy is suitable for the procedure.

Blinding:

To make sure the results are fair and unbiased:

  • Participants and their heart failure doctors will not know whether the patient received the treatment or the sham procedure.
  • The doctor performing the procedure and certain study staff will know which procedure is performed so they can carry out the procedure safely.
  • The study safety team will also know this information to help monitor patient safety.

Sham Procedure:

A sham procedure is used to help researchers understand whether any improvements are due to the treatment itself or to the placebo effect.

During the sham procedure:

A small needle puncture is made in the groin or neck, similar to what is done for many heart procedures.

Doctors check the veins to confirm whether the procedure could have been performed.

However, the treatment catheter is not used and the nerve is not treated.

The sham procedure takes about 45 minutes, which is about the same amount of time as the treatment procedure.

Number of Participants:

90 patients were assigned to treatment or sham during Phase I.

In Phase II, up to 60 additional patients will be enrolled.

About 40 patients will receive the treatment, and about 20 will receive the sham procedure.

Tipo de estudo

Intervencional

Inscrição (Estimado)

150

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35211
        • Concluído
        • Cardiology PC
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85016
        • Concluído
        • Arizona Cardiovascular Research Center
    • California
      • La Jolla, California, Estados Unidos, 92037
        • Recrutamento
        • Scripps Health
        • Investigador principal:
          • Rajeev Mohan, MD
        • Investigador principal:
          • Matthew Price, MD
        • Contato:
      • San Francisco, California, Estados Unidos, 94143
        • Recrutamento
        • University of California, San Francisco
        • Investigador principal:
          • Liviu Klein, MD
        • Contato:
      • San Francisco, California, Estados Unidos, 94143
        • Recrutamento
        • Zuckerberg San Francisco General Hospital and Trauma Center
        • Contato:
        • Investigador principal:
          • Lucas ZIer, MD
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30901
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Bluhm Cardiovascular Institute of Northwestern University
        • Investigador principal:
          • Ravi Patel, MD
        • Contato:
      • Chicago, Illinois, Estados Unidos, 60637
      • Springfield, Illinois, Estados Unidos, 62701
        • Concluído
        • Prairie Education and Research Cooperative
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Concluído
        • Ascension St. Vincent - Cardiovascular Research Institute
    • Louisiana
      • Houma, Louisiana, Estados Unidos, 70360
        • Recrutamento
        • Cardiovascular Institute of the South
        • Investigador principal:
          • Peter Fail, MD
        • Contato:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • Michigan Medicine, University of Michigan
        • Investigador principal:
          • Scott Hummel, MD
        • Contato:
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic
        • Investigador principal:
          • Barry Borlaug, MD
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63136
        • Recrutamento
        • St. Louis Heart and Vascular
        • Investigador principal:
          • Gil Vardi, MD
        • Contato:
    • New York
      • New York, New York, Estados Unidos, 10021
        • Recrutamento
        • Weill Cornell Medicine
        • Investigador principal:
          • Parag Goyal, MD
        • Contato:
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • Columbia University Medical Center
        • Investigador principal:
          • Nir Uriel, MD
        • Contato:
      • New York, New York, Estados Unidos, 10029
        • Concluído
        • Icahn School of Medicine at Mount Sinai
      • Rochester, New York, Estados Unidos, 14621
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Recrutamento
        • Duke University Medical Center
        • Investigador principal:
          • Marat Fudim, MD, MHS
        • Contato:
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • Ainda não está recrutando
        • The Christ Hospital
        • Investigador principal:
          • Odayme Quesada, MD
        • Contato:
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • Ohio State University Wexner Medical Center
        • Investigador principal:
          • Alexandria Miller, MD
        • Contato:
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Recrutamento
        • Medical University of South Carolina
        • Investigador principal:
          • Sheldon Litwin, MD
        • Contato:
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Baylor College of Medicine
        • Investigador principal:
          • Ajith Nair, MD
        • Contato:
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23298
        • Concluído
        • Virginia Commonwealth University Medical Center
      • Tbilisi, Geórgia
        • Recrutamento
        • Tbilisi Heart and Vascular Center
        • Investigador principal:
          • Tamaz Shaburishvili, MD
        • Contato:
      • Tbilisi, Geórgia
        • Ativo, não recrutando
        • Tbilisi Heart Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

40 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria

  1. Chronic heart failure, defined as:

    1. Symptoms of HF requiring current (intermittent or continuous) treatment with diuretics for >30 days, AND
    2. NYHA class II with a history of >NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND
    3. At least one of the following:

    i. ≥1 HF hospital admission (with HF as the primary diagnosis) including treatment with intravenous (IV) diuretics or urgent unplanned treatment with IV diuretics in healthcare facility within past 12 months, OR ii. NT-proBNP >300 pg/ml in normal sinus rhythm (>450 pg/ml in atrial fibrillation or flutter) within the past 6 months; BNP >100 pg/ml in normal sinus rhythm (>300 pg/ml in atrial fibrillation or flutter) within the past 6 months, OR iii. Right heart catheterization (RHC) with PCWP ≥ with PCWP ≥18 mmHg at rest or 25 mmHg during exercise at the time of the screening RHC.

  2. Ongoing stable GDMT HF management (unless unable to tolerate GDMT) and management of potential comorbidities according to the 2022 ACCF/AHA Guideline for the Management of Heart Failure (Class 1 and 2a recommendations), with no significant changes [≥100% increase or ≥50% decrease] for a minimum of 1 month (30 days) prior to screening, that is expected to be maintained without change for at least 6 months. Participants cannot have started a glucagon-like peptide (GLP)-1 or gastric inhibitory peptide (GIP) agonist within the last 6 months or plan to start a GLP-1 or GIP agonist within the ensuing 6 months after enrollment.

  3. LVEF ≥50% (site-determined by transthoracic echocardiography) within the past 6 months.

  4. Age ≥40 years.

  5. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

Exclusion Criteria:

  1. MI (type I) and/or percutaneous cardiac intervention within 3 months prior to screening; CABG in past 3 months prior to screening, or current indication for coronary revascularization.

  2. Cardiac resynchronization therapy initiated within 3 months prior to screening.

  3. Advanced heart failure defined as one or more of the following:

    1. ACC/AHA/ESC Stage D HF or non-ambulatory NYHA Class IV HF.
    2. Inotropic infusion (continuous or intermittent) within 6 months prior to screening.
    3. Subject is on the cardiac transplant waiting list.
    4. Presence of or prior history of mechanical circulatory support for HF.
  4. Poor left heart compliance as determined by pulse-wave Doppler transmitral early-to-late (E/A) ratio >2.0 assessed by the screening echocardiogram. The Screening Committee will evaluate left heart function if the transmitral A velocity is not measurable or absent.

  5. Right heart dysfunction defined as tricuspid annular plane systolic excursion (TAPSE) <12 mm or right ventricular (RV) fractional area change (FAC) <25% assessed by the screening echocardiogram.

  6. Body mass index (BMI) >45 kg/m2.

  7. 6-minute walk test distance <100 meters OR >450 meters.

  8. Admission for HF within the 30 days prior to planned index procedure.

  9. Any known history of orthostatic hypotension or orthostatic hypotension at the time of screening (regardless of the presence of symptoms). Orthostatic hypotension is defined as a systolic blood pressure (BP) decrease of >20 mmHg upon going from supine to standing position or undergoing treatment with Midodrine.

  10. Orthostatic pulse pressure change from supine to standing decrease of >10mmHg in the absence of a HR increase >15bpm

  11. Postural orthostatic tachycardia syndrome or preload insufficiency syndrome.

  12. Systolic BP <100 mmHg or >170 mmHg despite appropriate medical management.

  13. Baseline screening ECG resting HR >100 beats per minute or ventricular tachycardia.

  14. Catheter ablation for atrial fibrillation within 6 months prior to screening or planned in the next 12 months at the time of screening.

  15. Left ventricular EF <40% within the 3 years prior to screening unless reduced EF was transient and associated with an acute event.

  16. Presence of significant valve disease defined by the site cardiologist as:

    1. Greater than mild mitral valve stenosis.
    2. Greater than moderate mitral valve regurgitation.
    3. Greater than moderate-to-severe tricuspid valve regurgitation.
    4. Greater than moderate aortic valve stenosis or regurgitation.
  17. Known hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis).

  18. History of clinically significant liver cirrhosis.

  19. Prior weight loss surgery

  20. Dialysis dependent; or estimated GFR <25 ml/min/1.73 m2 by CKD-EPI creatinine equation.

  21. Arterial oxygen saturation <90% on room air.

  22. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation of chronic pulmonary disease (including intubation) in the 12 months before study entry OR known history of GOLD Class III or worse chronic obstructive pulmonary disease (COPD).

  23. Participating in conflicting investigational drug or device study that is not completed within 30 days prior to the screening visit.

  24. Life expectancy <12 months for non-cardiovascular reasons.

  25. Any condition, or history of illness or surgery that, in the opinion of the site investigator or Screening Committee, might confound the results of the study or pose additional risks to the patient.

  26. Females who are pregnant or lactating or planning to become pregnant during the next year.

  27. Any of the following measured by screening right heart catheterization:

    1. Mean right atrial pressure (RAP) >20 mmHg at rest
    2. Cardiac index <2.0 L/min/m2 at rest
    3. Pulmonary vascular resistance (PVR) >4 Wood units

    Exclusion Criteria Assessed During the index procedure:

  28. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Greater Splanchnic Nerve Ablation

After anesthesia is given, doctors will use the Satera Ablation System to reach a nerve called the right greater splanchnic nerve. Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.

The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.

Comparador Falso: Sham Control Arm

After anesthesia is given, doctors will place a small tube into a vein. The steps and length of the procedure will be similar to the Axon treatment procedure, but the study treatment will not be performed.

During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Primary Safety Endpoint: Device or procedure related serious adverse events
Prazo: 1 Month

Evaluation of device or procedure-related serious adverse events at 1-month follow-up based on Clinical Events Committee (CEC) assessment

1 Month
Primary Efficacy Endpoint: KCCQ (6 months)
Prazo: Baseline through 6-months

Assessment of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 6-month follow up visit

Baseline through 6-months
Primary Efficacy Endpoint: 6MWT (6 months)
Prazo: Baseline through 6 months

Assessment of change in Six Minute Walk Test (6MWT) from baseline to the 6-month follow up visit

Baseline through 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Pulmonary Capillary Wedge Pressure (PCWP)
Prazo: Baseline through 1-month

Change in pulmonary capillary wedge pressure (PCWP) at resting, legs up, 20 Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit

Baseline through 1-month
Stress blood volume
Prazo: Baseline through 1-month

Change in estimated stress blood volume at resting, legs up, 20Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit.

Baseline through 1-month
NT-proBNP
Prazo: Baseline through 24-months

Change in NT-proBNP levels from Baseline through the 24-month visit

Baseline through 24-months
KCCQ (24-months)
Prazo: Baseline through 24-months

Change in KCCQ scores from baseline through the 24-month visit

Baseline through 24-months
6MWT (24-months)
Prazo: Baseline through 24-months

Change in 6MWT from Baseline through the 24-month visit

Baseline through 24-months
Time to first heart failure event
Prazo: Treatment through 24-months

Time to first heart failure event (hospitalizations and worsening heart failure events) through the 24-month visit

Treatment through 24-months
Incidence of heart failure events
Prazo: Treatment through 24-months

Incidence of heart failure events (hospitalizations and worsening heart failure events) through the 24-month visit

Treatment through 24-months
Hierarchical composite endpoint (12-months)
Prazo: Baseline through 12-months

Composite endpoint of cardiovascular death, heart failure events, and changes in KCCQ from Baseline to the 12-month visit

Baseline through 12-months
Incidence of serious device related cardiac or vascular events
Prazo: Treatment through 12- and 24-months

Assessment of the incidence of serious device related cardiac or vascular events through 12- and 24-months

Treatment through 12- and 24-months
Device or procedure related pain
Prazo: Treatment through 24-months

Assessment of device or procedure related pain lasting at least 30 days and requiring medical management

Treatment through 24-months
Orthostatic hypotension
Prazo: Treatment through 12- and 24-months

Incidence of new orthostatic hypotension up to 12- and 24-months

Treatment through 12- and 24-months
Acute Kidney Injury (AKI)
Prazo: Baseline through 12-and 24-months

Incidence of AKI requiring renal replacement therapy up to 12- and 24-months

Baseline through 12-and 24-months
Glomerular Filtration Rate (GFR)
Prazo: Baseline through 12- and 24-months

Incidence of worsening GFR (defined as >50% for at least 30 days in duration) up to 12- and 24-months

Baseline through 12- and 24-months
Adverse Events
Prazo: Procedure through 12- and 24-months

Incidence of all Adverse Events through 12- and 24-months

Procedure through 12- and 24-months
Mortality
Prazo: Procedure through 6-, 12- and 24-months

Incidence of all mortality for up to 6-, 12-, and 24-months summarized as all-cause mortality, CV mortality, or heart failure-related

Procedure through 6-, 12- and 24-months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Exploratory endpoint: Heart failure related medication changes (24-months)
Prazo: Baseline through 24-months

Freedom from heart failure related medication changes through the 24-month visit

Baseline through 24-months
Exploratory Endpoint: Diuretic medication (24-months)
Prazo: Baseline through 24-months

Change in diuretic dose through the 24-month visit

Baseline through 24-months
Exploratory Endpoint: Diastolic function (24-months)
Prazo: Baseline through 24-months

Assessment of diastolic function by transthoracic echocardiography evaluated over time from baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: C-reactive protein
Prazo: Baseline through 24-months

Change in c-reactive protein levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Aldosterone (ALD)
Prazo: Baseline through 24-months

Change in aldosterone levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Renin
Prazo: Baseline through 24-months

Change in Renin levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Weight
Prazo: Baseline through 24-months

Change in weight from Baseline through 24-months

Baseline through 24-months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Sanjiv S Shah, MD, Northwestern University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

18 de dezembro de 2020

Conclusão Primária (Estimado)

10 de janeiro de 2028

Conclusão do estudo (Estimado)

10 de agosto de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

7 de outubro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de outubro de 2020

Primeira postagem (Real)

19 de outubro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 09868

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever